Paradigm Biocapital Advisors’s Oyster Point Pharma, Inc. Common Stock OYST Stock Holding History

Paradigm Biocapital Advisors’s Portfolio OYST Stock Details OYST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,648,316	Closed	-$9.26M	–	31
2022 Q3	$9.26M	Buy	1,648,316 +314,986	+24%	+$1.97M	1.24%	24
2022 Q2	$5.77M	Buy	1,333,330 +345,632	+35%	+$1.96M	1.15%	20
2022 Q1	$11.5M	Buy	987,698 +683,460	+225%	+$8.14M	3.04%	16
2021 Q4	$5.55M	Buy	+304,238	New	+$3.86M	1.59%	21

Other funds holding OYST

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Paradigm Biocapital Advisors's OYST Position: Q4 2022 in Review

Paradigm Biocapital Advisors sold out of Oyster Point Pharma, Inc. Common Stock (OYST) in Q4 2022, closing a stake of 1,648,316 shares — an estimated $9.26M sold.

Paradigm Biocapital Advisors first reported a position in OYST in Q4 2021 and held it in 4 quarters. The position peaked at $11.5M in Q1 2022. 53 funds tracked by Wall St. Rank hold OYST as of Q4 2022.

Paradigm Biocapital Advisors reported no remaining Oyster Point Pharma, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Paradigm Biocapital Advisors sold 1,648,316 Oyster Point Pharma, Inc. Common Stock shares in Q4 2022, an estimated $9.26M.
Paradigm Biocapital Advisors first reported a position in Oyster Point Pharma, Inc. Common Stock in Q4 2021 and held it in 4 quarters.
Paradigm Biocapital Advisors's Oyster Point Pharma, Inc. Common Stock position peaked at $11.5M in Q1 2022.
53 funds tracked by Wall St. Rank held Oyster Point Pharma, Inc. Common Stock as of Q4 2022.

Based on Paradigm Biocapital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.